Insulin-like growth factor 5 associates with human Aß plaques and promotes cognitive impairment.
Stefanie RauskolbThomas AndreskaSophie FriesCora Ruedt von CollenbergRobert BlumCamelia-Maria MonoranuCarmen VillmannMichael SendtnerPublished in: Acta neuropathologica communications (2022)
Risk factors such as dysregulation of Insulin-like growth factor (IGF) signaling have been linked to Alzheimer's disease. Here we show that Insulin-like Growth Factor Binding Protein 5 (Igfbp5), an inhibitory binding protein for insulin-like growth factor 1 (Igf-1) accumulates in hippocampal pyramidal neurons and in amyloid plaques in brains of Alzheimer patients. We investigated the pathogenic relevance of this finding with transgenic mice overexpressing Igfbp5 in pyramidal neurons of the brain. Neuronal overexpression of Igfbp5 prevents the training-induced increase of hippocampal and cortical Bdnf expression and reduces the effects of exercise on memory retention, but not on learning acquisition. Hence, elevated IGFBP5 expression could be responsible for some of the early cognitive deficits that occur during the course of Alzheimer's disease.
Keyphrases
- binding protein
- growth hormone
- cerebral ischemia
- cognitive decline
- risk factors
- cognitive impairment
- end stage renal disease
- poor prognosis
- spinal cord
- endothelial cells
- chronic kidney disease
- cell proliferation
- high glucose
- peritoneal dialysis
- physical activity
- subarachnoid hemorrhage
- multiple sclerosis
- spinal cord injury
- white matter
- oxidative stress
- blood brain barrier
- induced pluripotent stem cells
- resting state
- mild cognitive impairment
- signaling pathway
- body composition
- functional connectivity
- brain injury
- drug induced
- high resolution
- pluripotent stem cells
- virtual reality